Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
HUDSON, N.H., Sept. 08, 2016 -- S-BIO1 has launched today EZGlycoTM mAb-N Kit with 2-AB, a breakthrough new product that enables scientists to analyze N-glycans in IgG and Fc-fusion proteins from culture supernatant samples in a rapid, simplified and streamlined single tube operation. The kit is a valuable tool supporting customers in glycoprotein characterization for biotherapeutic development.
Therapeutic monoclonal antibodies (IgG, mAb) are routinely expressed in recombinant expression systems. N-glycosylation is one of the most important post-translational modifications. Monitoring of glycosylation in antibody development and production directly from cell culture media will shorten the time needed to obtain the N-glycan profiling. HPLC-ready glycan preparation can be performed in less than 2 hours, allowing scientists to purify IgG from cell culture supernatant, release and label N-glycans in one complete kit. “The EZGlyco mAb-N Kit with 2-AB streamlined and rapid N-glycan preparation from IgG cell culture supernatant circumvents use of other kits for IgG purification and provides unmatched speed, ease of use, and compatibility with HPLC,” states Dr. Anju M. Dang, Director, S-BIO.
The new EZGlycoTM mAb-N Kit with 2-AB is currently available in the U.S. through S-BIO, Vaupell Holdings Inc. (http://s-bio.com/products/ezglyco-mab-n/), a Sumitomo Bakelite Co., Ltd. group company.
About S-BIO
S-BIO is a division of Sumitomo Bakelite Co., Ltd. (a pioneer in plastics with products used for wide-ranging applications such as IT components and material, high performance plastics and quality-of-life product). S-BIO’s main product and services fall into two categories: glycan analysis related services and products, and high performance labware for cell culture applications.
Glossary
1S-BIO, U.S.
S-BIO is a division of Sumitomo Bakelite that specializes in providing glycan analysis products and tools to advance glycomics research, and 3D cell culture plates for cancer and stem cell research.
S-BIO’s analytical services are based on a proprietary GlycanMap® platform, which provides rapid and efficient analysis of both N-linked and O-linked glycans in glycoproteins. GlycanMap® technology combines BlotGlyco® bead-based glycan purification in a fully automated sample processing system with high-throughput MALDI-TOF mass spectrometry to generate rapid, reproducible glycan profiles for bioprocess and biomarker discovery. With an established laboratory at Hudson, NH, S-BIO supports the advancement of customer needs in the fields of drug discovery, regenerative medicine, stem cell and cancer research, and glycobiology.
Registered trademarks are trademarks of their respective companies.
Anju M. Dang, Ph.D. S-BIO, Sumitomo Bakelite Co., Ltd. Tel: (603) 425-9697 E-mail: [email protected]
